Amphastar Pharmaceuticals Business Summary

Amphastar Pharmaceuticals, Inc. (AMPH) operates as a vertically integrated specialty pharmaceutical company that generates revenue primarily through the manufacturing and sale of technically challenging generic and proprietary products, including injectables, inhalation, and intranasal therapies. The company’s business is concentrated in three primary segments: high-barrier generic injectables (e.g., glucagon, epinephrine), proprietary branded products (notably BAQSIMI and Primatene MIST), and insulin active pharmaceutical ingredients (API). Amphastar distinguishes itself by targeting niche markets with significant technical or regulatory hurdles, such as complex delivery systems and biosimilars. In the competitive landscape, it contends with global giants like Teva Pharmaceutical, Viatris, Hikma Pharmaceuticals, and Fresenius Kabi. Within this group, Amphastar maintains a commanding position as a top-five player in the U.S. generic injectables market, leveraging its internal API production to mitigate supply chain volatility and sustain higher margins than commoditized generic manufacturers. The company was co-founded in 1996 by Dr. Jack Yongfeng Zhang and Dr. Mary Ziping Luo, both of whom continue to lead the organization with deep technical pedigrees. Dr. Zhang serves as the Chief Executive Officer, President, and Chief Scientific Officer, bringing over 40 years of experience in chemistry and physics to the firm’s R&D strategy. Dr. Luo, the Chief Operating Officer and Chairwoman, is a professor emeritus of chemistry with a background from Princeton and Caltech, overseeing the company’s scientific leadership and intellectual property portfolio. The executive team is further bolstered by CFO William J. Peters, who joined in 2014 following a decade-long tenure as CFO of Hi-Tech Pharmacal. The Board of Directors includes notable industry veterans such as Lead Independent Director Richard Prins and Dr. Howard Lee, who brings extensive experience from the healthcare venture capital and investment banking sectors.